They provide a model useful to study <em>in vivo</em> mechanisms of xenogeneic GVHD and to rapidly assess therapeutic agents. <br /><br />These NSG-MHC I/II DKO mice are also …

Here, we report that dystrophin-utrophin double knockout (dko) mice exhibit a spectrum of degenerative changes, outside skeletal muscle, in bone, articular cartilage, and intervertebral …

Five-week-old dko−/− mice were age-matched with control animals and a spherical, unicortical defect was surgically created in the proximal tibia. The mice were followed with serial micro …

The NCG-MHC-dKO is a triple immunodeficient NCG mouse that lacks expression of the MHC class I molecule (H2-K and H2-D1), and MHC class II molecule (H2-Ab1). Lack of expression …

The dystrophin−/−/utrophin−/−/ double knockout (dKO-Hom) mouse is a murine model of human Duchenne muscular dystrophy. This study investigated the bone and muscle abnormalities of …

Mar 12, 2025 · In the present study, we treated double knockout (dKO) mice, invalidated for both dystrophin and utrophin expression, with adeno-associated virus (AAV)2/9-Spc5.12-MD1 (AAV …

Aug 22, 1997 · Double-knockout (dko) mice (mdx/utrn−/−) show many more of the clinical signs of DMD than mdx mice, which show no phenotypic signs of their underlying muscle pathology …

In this study, we examined the effect of peptide-conjugated PMO (PPMO)-mediated exon skipping on disease progression of utrophin-dystrophin-deficient mice (dko) of four age groups (21–29, …

NKG mice are a type of severe immunodeficient mouse developed by Cyagen by deleting the Il2rg gene from the NOD-Scid strain. This strain lacks mature T, B, and NK cells, has reduced …

May 1, 2023 · Based on our preliminary data, the NCG-MHC-dKO mouse is a promising model for evaluating antibody and cell therapy agents, assessing treatment-related cytokine release …